Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans
- 14 February 2003
- journal article
- clinical trial
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (2) , 339-347
Abstract
A number of studies have reported decreased human lumbar cerebrospinal fluid (CSF) concentrations of the major serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), following chronic administration of selective serotonin reuptake inhibitors (SSRIs). This decrease has been thought to be a consequence of elevated extracellular serotonin and to be mediated through terminal autoreceptor feedback inhibition of serotonin turnover. We wished to study the previously unexamined acute effects of SSRI administration on human CSF 5-HIAA. A serial lumbar puncture (LP) procedure was used to collect CSF samples before and after a single oral 40 mg dose of the SSRI paroxetine (PAR) or matching placebo in eight healthy adult humans in a randomized, double-blind fashion. CSF 5-HIAA concentrations did not change following placebo, but showed a statistically significant 27% mean increase 3 h following PAR. Our findings stand in contrast to the decreases reported for CSF 5-HIAA after chronic SSRI treatment in humans and the decreases seen in brain extracellular 5-HIAA after acute or chronic administration of SSRIs to animals.Keywords
This publication has 39 references indexed in Scilit:
- In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administrationSynapse, 2000
- Selective serotonin reuptake inhibitors and neuroendocrine functionLife Sciences, 1999
- Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human femalesLife Sciences, 1997
- Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysisLife Sciences, 1994
- Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nucleiSynapse, 1993
- Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortexBrain Research, 1992
- General Versus Systematic Inquiry about Emergent Clinical Events with SAFTEEJournal of Clinical Psychopharmacology, 1992
- Pharmacological Differences of Serotonin Reuptake Inhibitors and Possible Clinical RelevanceDrugs, 1992
- Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolitesActa Psychiatrica Scandinavica, 1989
- Elevated CSF dynorphin A [1–8] in Tourette's syndromeLife Sciences, 1988